3,5-二氯-2-甲氧基苯甲酸 | 22775-37-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氯-2-甲氧基苯甲酸
• 中文别名: 苯甲酸,3,5-二氯-2-甲氧基-；3,5-二氯-邻甲氧基苯甲酸
• 英文名称: 3,5-dichloro-2-methoxybenzoic acid
• 英文别名: 2-Methoxy-3,5-dichlorbenzoesaeure
• CAS: 22775-37-7
• 化学式: C₈H₆Cl₂O₃
• mdl: MFCD00017545
• 分子量: 221.04
• InChiKey: AUVSCSCAPKFMEK-UHFFFAOYSA-N

物化性质

• 熔点：
  166-167 °C
• 沸点：
  333.2±37.0 °C(Predicted)
• 密度：
  1.474±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2918990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 3,5-Dichloro-2-methoxybenzoic acid
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Eye irritation (Category 2)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H319 Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36 Irritating to eyes.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C8H6Cl2O3
Molecular Weight : 221,04 g/mol
Component Concentration
3,5-Dichloro-2-methoxybenzoic acid
-

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 3,038
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,5-二氯-2-甲氧基苯甲酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 反应 1.5h， 生成 3,5-dichloro-2-methoxybenzoyl chloride
  参考文献：
  名称：

  将卤水杨酰胺衍生物鉴定为一类新型 HCV NS5B 聚合酶变构抑制剂。

  摘要：

  卤水杨酰胺衍生物通过高通量筛选被鉴定为 HCV NS5B 聚合酶的有效抑制剂。随后的结构和活性关系揭示了水杨酰胺部分对最佳活性的绝对要求。水杨酰胺部分的羟基或酰胺基团的甲基化消除了活性，而两个苯环上的取代是可接受的。卤代水杨酰胺衍生物在延伸核苷酸方面显示出非竞争性，并显示出针对基因型 1-3 HCV NS5B 聚合酶的广泛基因型活性。抑制剂竞争研究表明与噻二嗪类化合物占据的起始口袋的加性结合模式和由二酮酸占据的延伸口袋的加性结合模式，但是对于被苯并咪唑类抑制剂占据的变构拇指口袋而言，这是一种相互排斥的结合模式。因此，卤代水杨酰胺代表了一类新型的 HCV NS5B 聚合酶变构抑制剂。

  DOI：

  10.1016/j.bmcl.2008.04.068
• 作为产物：
  描述：

  4,6-二氯甲酚 在 甲醇 、 氢氧化钾 、 硝酸 作用下， 生成 3,5-二氯-2-甲氧基苯甲酸
  参考文献：
  名称：

  Martini, Gazzetta Chimica Italiana, 1899, vol. 29 II, p. 60

  摘要：

  DOI：

文献信息

• Structural Development of Salicylanilide‐Based SPAK Inhibitors as Candidate Antihypertensive Agents
  作者：Shinya Fujii、Eriko Kikuchi、Honoka Suzuyama、Yuko Watanabe、Mari Ishigami‐Yuasa、Hiroyuki Masuno、Takayasu Mori、Kiyoshi Isobe、Shinichi Uchida、Hiroyuki Kagechika

  DOI：10.1002/cmdc.202100273

  日期：2021.9.16

  proline-alanine-rich protein kinase (SPAK)-NaCl cotransporter (NCC) signal cascade as a potential target, and we previously developed a screening system for inhibitors of WNK-OSR1/SPAK-NCC signaling. Herein we used this system to examine the structure-activity relationship (SAR) of salicylanilide derivatives as SPAK kinase inhibitors. Structural design and development based on our previous hit compound, aryloxybenzanilide

  高血压是药物发现的重要目标。我们专注于无赖氨酸激酶 (WNK)-氧化应激反应 1 (OSR1) 和 STE20/SPS1 相关的富含脯氨酸-丙氨酸蛋白激酶 (SPAK)-NaCl 协同转运蛋白 (NCC) 信号级联作为潜在的目标，我们之前开发了一种筛选系统，用于 WNK-OSR1/SPAK-NCC 信号传导抑制剂。在这里，我们使用该系统来检查水杨酰苯胺衍生物作为 SPAK 激酶抑制剂的构效关系 (SAR)。基于我们之前的热门化合物芳氧基苯甲酰苯胺衍生物2和兽用驱虫药 closantel ( 3 ) 的结构设计和开发导致发现化合物10a作为一种有效的、毒性降低的 SPAK 抑制剂。化合物10a降低了体内小鼠肾脏中 NCC 的磷酸化水平，并且似乎是一类有前途的新型抗高血压药物的先导化合物。
• [EN] ACLY INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'ACLY ET LEURS UTILISATIONS
  申请人：NIMBUS ARTEMIS INC

  公开号：WO2020097408A1

  公开（公告）日：2020-05-14

  The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

  本发明提供了作为ATP柠檬酸裂合酶（ACLY）抑制剂的化合物、其组合物以及使用方法。
• Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling
  作者：Shinya Fujii、Eriko Kikuchi、Yuko Watanabe、Honoka Suzuyama、Mari Ishigami-Yuasa、Takayasu Mori、Kiyoshi Isobe、Shinichi Uchida、Hiroyuki Kagechika

  DOI：10.1016/j.bmcl.2020.127408

  日期：2020.9

  structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK (STE20/SPS1-related proline/alanine-rich kinase) inhibitors. Abnormal activation of the signal cascade of with-no-lysine kinase (WNK) with OSR1 (oxidative stress-responsive kinase 1)/SPAK and NCC (NaCl cotransporter) results in characteristic salt-sensitive hypertension, and therefore inhibitors of the WNK-OSR1/SPAK-NCC

  我们在这里报告的N-（4-苯氧基苯基）苯甲酰胺衍生物作为新型SPAK（STE20 / SPS1相关脯氨酸/富含丙氨酸的激酶）抑制剂的结构发展。具有OSR1（氧化应激反应激酶1）/ SPAK和NCC（NaCl协同转运蛋白）的无赖氨酸激酶（WNK）信号级联的异常激活会导致特征性的盐敏感性高血压，因此是WNK-OSR1的抑制剂/ SPAK-NCC级联是抗高血压药物的候选药物。根据前导化合物2的结构，我们研究了N-（4-苯氧基苯基）苯甲酰胺衍生物的SAR ，并开发了作为有效SPAK抑制剂的化合物20l。化合物20l是新型抗高血压药的有希望的候选物。
• Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase
  作者：Yaya Liu、Pamela L. Donner、John K. Pratt、Wen W. Jiang、Teresa Ng、Vijaya Gracias、Steve Baumeister、Paul E. Wiedeman、Linda Traphagen、Usha Warrior、Clarence Maring、Warren M. Kati、Stevan W. Djuric、Akhteruzzaman Molla

  DOI：10.1016/j.bmcl.2008.04.068

  日期：2008.6

  elongation pocket that is occupied by diketoacids, but a mutually exclusive binding mode with respect to the allosteric thumb pocket that is occupied by the benzimidazole class of inhibitors. Therefore, halosalicylamides represent a novel class of allosteric inhibitors of HCV NS5B polymerase.

  卤水杨酰胺衍生物通过高通量筛选被鉴定为 HCV NS5B 聚合酶的有效抑制剂。随后的结构和活性关系揭示了水杨酰胺部分对最佳活性的绝对要求。水杨酰胺部分的羟基或酰胺基团的甲基化消除了活性，而两个苯环上的取代是可接受的。卤代水杨酰胺衍生物在延伸核苷酸方面显示出非竞争性，并显示出针对基因型 1-3 HCV NS5B 聚合酶的广泛基因型活性。抑制剂竞争研究表明与噻二嗪类化合物占据的起始口袋的加性结合模式和由二酮酸占据的延伸口袋的加性结合模式，但是对于被苯并咪唑类抑制剂占据的变构拇指口袋而言，这是一种相互排斥的结合模式。因此，卤代水杨酰胺代表了一类新型的 HCV NS5B 聚合酶变构抑制剂。
• Synthetic Studies on Indoles and Related Compounds. XXXVIII. .BETA.-Acylation of Ethyl Pyrrole-2-carboxylate by Friedel-Crafts Acylation: Scope and Limitations.
  作者：Masanobu TANI、Takahiro ARIYASU、Chika NISHIYAMA、Hiroko HAGIWARA、Toshiko WATANABE、Yuusaku YOKOYAMA、Yasuoki MURAKAMI

  DOI：10.1248/cpb.44.48

  日期：——

  The Friedel-Crafts acylation of ethyl pyrrole-2-carboxylate (3) was studied under several conditions using various Lewis acids and acyl chlorides. The acylation with various acyl chlorides in the presence of aluminum chloride gave exclusively ethyl 4-acylpyrrole-2-carboxylate (5), whereas weaker Lewis acids such as zinc chloride and boron trifluoride etherate gave a mixture of ethyl 4- and 5-acylpyrrole-2-carboxylates.

  在多种条件下，使用各种路易斯酸和酰基氯对吡咯-2-羧酸乙酯（3）的弗里德尔-卡夫酰化进行了研究。在有氯化铝存在的情况下，用各种酰基氯进行酰化反应，只得到 4-酰基吡咯-2-羧酸乙酯（5），而用氯化锌和三氟化硼醚酸等较弱的路易斯酸进行酰化反应，则得到 4-酰基吡咯-2-羧酸乙酯和 5-酰基吡咯-2-羧酸乙酯的混合物。